A case series on the safety of immunotherapy with reduced blood testing frequency in lung cancer patients.

Shoko KawaiKageaki WatanabeMaiko AsaiKana HashimotoTaiki HakozakiKosuke NaritaMakiko YomotaYukio Hosomi

Published in: International journal of clinical oncology (2021)

Our results indicate that immune checkpoint inhibitor administration without a blood test every 2 weeks did not subject patients to more adverse side effects.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
emergency department
drug induced